Articulus Bio Gains Funding, Focusing on Total Ankle Replacement

Articulus Bio received an undisclosed amount of funding from AngelMD. The company is developing a total ankle replacement, specifically addressing the issue of wear debris.

Articulus seeks capital to collect performance data on sub-assembly components of its Tendonoid™ Web Joint technology, which is designed to reduce and eliminate friction at articulating joint faces.

Tendonoid technology is based on a novel configuration of Ultra High Molecular Weight Polyethylene (UHMWPE), used to create an implant that "floats" the patient's weight on a web of UHMWPE cords to allow anatomical range of motion without wear debris generation. The total ankle device and custom jig are 3D-printed from CT scan data for just-in-time, per-patient use. Articulus intends to take lessons learned from its total ankle device and investigate application in other large and small joints.

Funds from AngelMD will also support pursuit of a Q-Submission meeting with FDA and the continued build of Articulus' intellectual property portfolio. 

Ankle replacements continue to drive the extremities recon market. Other ankle systems and devices making 2017 headlines included:

  • DT MedTech's FDA 510(k) clearance to market the Hintermann Series H2™ Total Ankle
  • Integra LifeSciences' implantation of the first Cadence® Total Ankle as part of a non-randomized, prospective, multi-center postmarket study
  • VirtaMed's introduction of ArthroS™ Ankle, reportedly the world’s first high-fidelity simulator for ankle arthroscopy
  • Wright Medical's first patient implantation in a U.S. follow-up study of the INFINITY™ Total Ankle